A Mathematical Model for the Treatment of Melanoma with the BRAF/MEK Inhibitor and Anti-PD-1

Skin cancer treatment is a combination of BRAF and MEK kinase inhibitors administered as tablets, along with immunotherapy (treatment into the vein) group drugs that inhibit activity immune barrier proteins PD-1 PDL1. Here, we propose new approach to therapy for melanoma BRAF/MEK inhibitor anti-PD-1. With help explicit analytical functions, were able model this combined present in mathematical described by system differential equations including variables, such Treg, IL12, Il10, TGF-β, cytokine, which are significant variables all critical factors determine effectiveness therapies. The most advantage functions control parameters, time dose, variable parameters treatment, is, these can be adapted patient’s personalized treatment. In current study, showed simultaneously changing combining two could decrease tumor volume. To validate numerical results, computed relative error between results obtained from clinical data.